Prognostic Value of Platelet Counts in Patients with Metastatic Prostate Cancer Treated with Endocrine Therapy
Vol. 17 No. 1 (2020),
26 January 2020
Purpose: The endocrine therapy is effective for patients with advanced prostate cancer, but the disease eventually becomes refractory to treatment. The aim of this study was to investigate prognostic factors and to develop a risk stratification model for survival in patients with advanced prostate cancer undergoing endocrine therapy.
Materials and Methods: This study included 197 patients with stage IV prostate cancer who were treated with endocrine therapy as primary treatment at Tokyo Medical University, Tokyo, Japan, between January 1999 and November 2012. Prognostic values including baseline clinical laboratory values before endocrine therapy for stage IV prostate cancer were examined. Patients (n = 30) who were not followed or for whom data were unavailable or who were treated with radiotherapy were excluded from the study. Excluding these patients, we retrospectively analyzed 167 patients who were treated with endocrine therapy as the primary treatment. Disease-specific survival (DSS) was evaluated using the Kaplan-Meier method, and prognostic factors were identified using the Cox proportional hazard model analysis.
Results: In univariate analyses, patients with a performance status (PS) ? 2, platelet count ? 3.0× 105 µ/L, prostate specific antigen (PSA) > 50 ng/mL, alkaline phosphatase (ALP) > 350 U/L, lactate dehydrogenase (LDH) > 240 IU/L, and Gleason score (GS) ? 8, hemoglobin (Hb) < 12 g/dL, extent of disease (EOD) ? 3 and poorly differentiated adenocarcinoma showed significantly lower DSS than their respective counterparts. Neutrophil-to-Lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR) and white blood cell (WBC) count were not significantly associated with DSS. In a multivariate Cox proportional hazard model, PS and platelet count were independent prognostic factors. Based on the hazard rate (HR) calculated by the following formula: HR = exp (0.82 × PS + 1.38 × platelet count) patients were stratified into 3 risk groups. The differences in DSS rates among the 3 groups were statistically significant.
Conclusion: These results suggest that PS and platelet count are independent prognostic factors and that a combination of these factors can be used to stratify metastatic prostate cancer patients treated with endocrine therapy according to their DSS risk.
How to Cite
Soloway MS, Hardeman SW, Hickey D,et al, Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer 1988; 61: 195-202.
L.J. Emrich, R.L. Priore, G.P. Murphy, et al, Prognostic factors in patients with advanced stage prostate cancer. Cancer Res 1985; 45: 5173-5179.
Tomioka A, Tanaka N, Yoshikawa M, et al Risk factors of PSA progression and overall survival in patients with localized and locally advanced prostate cancer treated with primary androgen deprivation therapy. BMC Cancer 2015; 15: 420.
Wang Y, Xu F, Pan J, et al Platelet to lymphocyte ratio as an independent prognostic indicator for prostate cancer patients receiving androgen deprivation therapy. BMC Cancer 2016; 16: 329
Templeton AJ, Pezaro C, Omlin A, et al Simple prognostic score for metastatic castration-resistant prostate cancer with incorporation of neutrophil-to-lymphocyte ratio. Cancer 2014; 120: 3346-3352
Bensalah K, Leray E, Fergelot P, et al Prognostic Value of Thrombocytosis in Renal Cell Carcinoma. J Urol 2006; 175: 859-63
Zhuo Y, Lin L, Zhang M et al Pretreatment thrombocytosis as a significant prognostic factor in malignant mesothelioma: a meta-analysis. Platelets 2016; 16: 1-7
Ochi Y, Kazuma Y, Hiramoto N et al Utility of a simple prognostic stratification based on platelet counts and serum albumin levels in elderly patients with diffuse large B cell lymphoma. Ann Hematol 2017; 96: 1-8
Georgios G, Hans-Martin F, Fahmy H, et al Prognostic relevance of postoperative platelet count in upper tract urothelial carcinoma after radical nephroureterectomy. Eur J Cancer 2014; 50: 2583-2591.
Stone RL, Nick AM, McNeish, et al Paraneoplastic Thrombocytosis in Ovarian Cancer. N Engl J Med 2012; 366: 610-618.
Dabrow MB, Francesco MR., Mc Breaty FX, et al The effects of platelet-derived growth factor and receptor on normal and neoplastic human ovarian surface epithelium. Gynecol Oncol 1998; 71: 29-37.
Reeves F, Sapre N, Corcoran N et al Tumor vascularity in prostate cancer: an update on circulating endothelial cells and platelets as noninvasive biomarkers. Biomark med. 2013, 7: 879-891.
Oken, M.M, Creech, R.H, Tormey, D.C et al Toxicity And Response
Criteria Of The Eastern Cooperative Oncology Group. Am J Clin Oncol, 1982 5:649-655.
Atzpodien J, Royston P, Wandert T, et al Metastatic renal carcinoma comprehensive prognostic system. Br J Cancer 2003; 88: 348-353.
Mizuno R, Nakashima J, Mukai M, et al Tumour length of the largest focus predicts prostate-specific antigen-based recurrence after radical prostatectomy in clinically localized prostate cancer. BJU 2009; 104: 1215-1218.
Ohno Y, Nakashima J, Ohori M, et al Pretreatment neutrophil-to-lymphocyte ratio as an independent predictor of recurrence in patients with nonmetastatic renal cell carcinoma. J Urol 2010; 184(3): 873-878.
Leblanc R, Peyruchaud O The role of platelets and megakaryocytes in bone metastasis. J Bone Oncol 2016; 5(3): 109-111.
Jae Y, Young H, Phil H Clinical significance of preoperative thrombocytosis in patients who underwent radical nephrectomy for nonmetastatic renal cell carcinoma. Original article-Urological Oncology 2016; 57: 324-329
Katsuki I, Kei K, Shunichi S, et al Prognostic significance of thrombocytosis in renal cell carcinoma patients. International Journal of Urology 2004; 11, 364-367.
Parado L, Valero C, Lopez M, et al The prognostic value of pretreatment platelet count in patients with head and neck squamous cell carcinoma. Auris Nasus Larynx 2017; 44 (3), 313-318
Ishizuka M, Oyama Y, Abe A, et al Combination of Platelet Count and Neutrophil to Lymphocyte Ratio is Useful Predictor of Postoperative Survival in Patients Undergoing Surgery for Gastric Cancer. J Surg Oncol 2014; 110: 935-941.
Fizazi K, Scher HI, Molina A, et al Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2012; 13: 983-992.
Ryan, CJ, Smith MR, Fizazi K, et al Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2015; 16: 152-160.
Beer TM, Andrew JA, Dana ER, et al Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 2014; 371: 424-433.
- Abstract Viewed: 504 times
- pdf/4735 Downloaded: 188 times